Literature DB >> 27162672

Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study.

Yun Li1, Yin-Huan Li1, Shuo Li1, Yu-Wen Luo1, Rui Xiao1, Yu-Xia Huang1, Jin-Lun Huang1, Yi-Tai Chen1, Rong-Chang Zhi1, Xin Chen1.   

Abstract

BACKGROUND: Conventional lung function parameters, such as forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and inspiratory capacity (IC) are often used to assess the therapeutic outcomes of bronchodilators, but they lack sensitivity. A novel indicator, namely efficiency of neural respiratory drive (NRD), may objectively evaluate the physiological changes in patients with chronic obstructive pulmonary disease (COPD). We investigated whether this indicator could be used to more accurately assess the responsiveness to inhaled bronchodilators.
METHODS: Thirty-six subjects with moderate-to-severe COPD were randomized into group A (n=18) and group B (n=18). Participants in group A inhaled 400 µg placebo, 400 µg salbutamol and 80 µg ipratropium in sequence whereas those in group B had the salbutamol and ipratropium reversed. At different time points after administration of placebo or bronchodilators, evaluated indices included FEV1, FVC, IC, root mean square (RMS) of diaphragm electromyogram (EMGdi), and efficiency of NRD [herein defined as the ratio of minute ventilation (VE) to RMS, or VE/RMS].
RESULTS: FEV1, FVC, IC, RMS, and VE/RMS significantly improved after inhaled bronchodilators and VE/RMS had the largest improvement among five indices. The detection efficiency of VE/RMS was greater than FEV1, FVC, IC (all P<0.05), but not different from RMS. The accuracy and sensitivity of VE/RMS were significantly higher than FEV1, FVC, IC, and RMS (all P<0.05).
CONCLUSIONS: Efficiency of NRD may be a sensitive tool to evaluate the efficacy of inhaled bronchodilators in COPD.

Entities:  

Keywords:  Chronic obstructive pulmonary disease (COPD); bronchodilator; neural respiratory drive (NRD); respiratory function tests

Year:  2016        PMID: 27162672      PMCID: PMC4842829          DOI: 10.21037/jtd.2016.03.70

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

1.  FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Donald A Mahler; Edward Kerwin; Tim Ayers; Angel FowlerTaylor; Samopriyo Maitra; Chau Thach; Mark Lloyd; Francesco Patalano; Donald Banerji
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

Review 2.  Neural respiratory drive measurement for COPD assessment and monitoring.

Authors:  Adam James Garland; Akash Doshi; Victor Turcanu
Journal:  Pneumologia       Date:  2015 Jan-Mar

3.  Evaluation of bronchodilator responses in patients with "irreversible" emphysema.

Authors:  D E O'Donnell; L Forkert; K A Webb
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

4.  Bronchodilator testing: confidence intervals derived from placebo inhalations.

Authors:  R L Sourk; K M Nugent
Journal:  Am Rev Respir Dis       Date:  1983-07

5.  Measurement of neural respiratory drive in patients with COPD.

Authors:  Y M Luo; J Moxham
Journal:  Respir Physiol Neurobiol       Date:  2005-04-15       Impact factor: 1.931

6.  Effect of tiotropium on neural respiratory drive during exercise in severe COPD.

Authors:  Yin-Yin Qin; Rui-Fa Li; Guo-Feng Wu; Zheng Zhu; Jie Liu; Cheng-Zhi Zhou; Wei-Jie Guan; Jia-Ying Luo; Xin-Xin Yu; Yang-Ming Ou; Mei Jiang; Nan-Shan Zhong; Yuan-Ming Luo
Journal:  Pulm Pharmacol Ther       Date:  2014-11-28       Impact factor: 3.410

7.  An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

Authors:  Mark B Parshall; Richard M Schwartzstein; Lewis Adams; Robert B Banzett; Harold L Manning; Jean Bourbeau; Peter M Calverley; Audrey G Gift; Andrew Harver; Suzanne C Lareau; Donald A Mahler; Paula M Meek; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2012-02-15       Impact factor: 21.405

8.  Short-term effects of inhaled beta-adrenergic agonist on breathlessness and central inspiratory drive in patients with nonreversible COPD.

Authors:  J M Pino-García; F García-Río; L Gómez; M A Racionero; S Díaz-Lobato; J Villamor
Journal:  Chest       Date:  1996-09       Impact factor: 9.410

9.  Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.

Authors:  M J Belman; W C Botnick; J W Shin
Journal:  Am J Respir Crit Care Med       Date:  1996-03       Impact factor: 21.405

10.  Neural respiratory drive in healthy subjects and in COPD.

Authors:  C J Jolley; Y-M Luo; J Steier; C Reilly; J Seymour; A Lunt; K Ward; G F Rafferty; M I Polkey; J Moxham
Journal:  Eur Respir J       Date:  2008-10-01       Impact factor: 16.671

View more
  2 in total

1.  Continuous positive airway pressure improves respiratory mechanics and efficiency of neural drive in stable COPD: an exploratory study.

Authors:  Kai Wang; Zhen-Yu Liang; Xi-Long Wang; Yun Li; Yi-Rong Lu; Jun-Fang Liu; Jia-Hui Li; Li-Mei Xu; Guo-Qiang Chen; Ping Chang; Zhong-Ran Cen; Xin Chen
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

2.  Does the Efficacy of High Intensity Ventilation in Stable COPD Depend on the Ventilator Model? A Bench-to-Bedside Study.

Authors:  Cristina Lalmolda; Pablo Flórez; Marta Corral; Ana Hernández Voth; Carles Grimau; Javier Sayas; Manel Luján
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.